Five drug companies told to recall diabetes medication amid cancer fears
Drug widely used to reduce excess blood sugar in type 2 diabetes patients
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.Five US pharmaceutical companies have been told to recall their versions of a type of diabetes medication after tests found worrying levels of a chemical linked to cancer.
Several batches of metformin, which is widely used to reduce excess blood sugar in type 2 diabetes patients, tested positive for unsafe levels of N-Nitrosodimethylamine, the Food and Drug Administration (FDA) said on Thursday.
The FDA advised that patients should continue to take metformin until a replacement can be prescribed, acknowledging the risks of discontinuing the medication for patients.
Apotex Corp has recalled its supplies of the drug this week after the FDA found one of its lots to be contaminated.
The company said in a statement that it recalled all supplies of extended-release metformin “out of an abundance of caution”, and that it stopped selling the drug in the US in Febuary 2019 and little is still on the market.
The four other companies that have been requested to recall the product were not named in the FDA announcement.
The health and safety agency noted that immediate-release metformin had not been found to be contaminated.
Regulators have said that a number of other companies make versions of the drugs that don’t appear to be similarly affected.
The FDA increased testing after the same chemical was found in dozens of shipments of heartburn drugs last year.
As a result, a similar recall was ordered for over the counter and prescription heartburn medications such as Zantac.
Regulators are still assessing whether the recalls will lead to shortages of metformin across the country, where more than 34 million people in the US live with type 2 diabetes.
Additional reporting by The Associated Press
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments